ArticleNature microbiology2018
Mycobacterium tuberculosis carrying a rifampicin drug resistance mutation reprograms macrophage metabolism through cell wall lipid changes.
Erratum issuedOpen access · greenAbstract read
In one paragraph
Article in Nature microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 71 papers.
0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed
7.8field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 114 citations in OpenAlex.
- Sequential gene loss promotes expansion of monophasic Salmonella Typhimurium ST34.Nature microbiology · 2026Article
- Protein kinase F regulates the virulence ofInfection and immunity · 2026Article
- Mycobacterium tuberculosis IDH-PPARγ interaction suppresses GPX4 to drive macrophage ferroptosis and sustain persistent infection.Nature communications · 2026Article
- Transcription attenuation amplifies collateral vulnerabilities in rifampicin-resistant Mycobacterium tuberculosis.Nature microbiology · 2026Article
- Article
- The lipid language of tuberculosis:mBio · 2026Review
- Infection with Mycobacterium tuberculosis depletes host fatty acids in humans and non-human primates.EBioMedicine · 2026Article
- Increased risk of antimicrobial resistance in patients with cirrhosis and hepatic encephalopathy using rifaximin.Nature communications · 2025Article
- Protein kinase F regulates the virulence ofbioRxiv : the preprint server for biology · 2025Article
- Scutellarin suppresses Mycobacterium tuberculosis-induced pyroptosis in macrophages by inhibiting the HIF-1α-mediated Warburg effect.Redox report : communications in free radical research · 2025Article
- Evaluation of thermal desorption-electrospray ionization mass spectrometry for characterization ofJournal of mass spectrometry and advances in the clinical lab · 2025Article
- Mycobacterial phthiocerol dimycocerosate induces Galectin-3 upregulation to impair proinflammatory responses and favor immune evasion.International journal of biological macromolecules · 2025Article
- Structure and assembly of the MmpL5/MmpS5 efflux transporter from Mycobacterium tuberculosis.Nature communications · 2025Article
- Genetically Diverse Mycobacterium tuberculosis Isolates Manipulate Inflammasome and Interleukin 1β Secretion Independently of Macrophage Metabolic Rewiring.The Journal of infectious diseases · 2025Article
- Identification and assessment of hub genes and miRNAs coregulatory associated with immune infiltrations and drug interactions in latent tuberculosis based on MicroarrayData analysis, molecular docking, and dynamic simulation.Biochemistry and biophysics reports · 2025Article
- Pathogenic role for CD101-negative neutrophils in the type I interferon-mediated immunopathogenesis of tuberculosis.Cell reports · 2025Article
- Inclusion of patient-centered, non-microbiological endpoints and biomarkers in tuberculosis drug trials.Frontiers in antibiotics · 2025Review
- Mitophagy: A Potential Therapeutic Target for Tuberculosis Immunotherapy.ImmunoTargets and therapy · 2025Review
- Influence of cell bioenergetics on host-pathogen interaction in the lung.Frontiers in immunology · 2025Review
- Drug resistant Mycobacterium tuberculosis strains have altered cell envelope hydrophobicity that influences infection outcomes in human macrophages.Scientific reports · 2024Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
21 authors at 7 institutions in 2 countries.
Nicole C HowardDepartment of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, USA.
Nancy D MarinDepartment of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, USA.
Mushtaq AhmedDepartment of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, USA.
Bruce A RosaDepartment of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
John MartinDepartment of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Monika BambouskovaDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.
Alexey SergushichevComputer Technologies Department, ITMO University, Saint Petersburg, Russia.ORCID http://orcid.org/0000-0003-1159-7220
Ekaterina LoginichevaDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.
Natalia KurepinaPublic Health Research Institute, New Jersey Medical School, Rutgers University, Newark, NJ, USA.
Javier Rangel-MorenoDivision of Allergy/Immunology and Rheumatology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.
Liang ChenPublic Health Research Institute, New Jersey Medical School, Rutgers University, Newark, NJ, USA.
Barry N KreiswirthPublic Health Research Institute, New Jersey Medical School, Rutgers University, Newark, NJ, USA.
Robyn S KleinDepartment of Medicine, Washington University School of Medicine, St. Louis, MO, USA.ORCID http://orcid.org/0000-0003-0281-1352
Joan-Miquel Balada-LlasatDepartment of Pathology, The Ohio State University, Columbus, OH, USA.
Jordi B TorrellesDepartment of Microbial Infection and Immunity, The Ohio State University, Columbus, OH, USA.
Gaya K AmarasingheDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.
Makedonka MitrevaDepartment of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Maxim N ArtyomovDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.
Fong-Fu HsuDepartment of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Barun MathemaDepartment of Epidemiology, Columbia University Mailman School of Public Health, New York, NY, USA.
Shabaana A KhaderDepartment of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, USA. sakhader@wustl.edu.ORCID http://orcid.org/0000-0002-9545-4982
Washington University in St. Louis · USRutgers, The State University of New Jersey · USColumbia University · USITMO University · RUTexas Biomedical Research Institute · USThe Ohio State University · USUniversity of Rochester · US
Funding
Washington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI TIMOTHY J. EBERLEIN · 2001 to 2026
$128.0MWU INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCESUL1TR002345 · NCATS · WASHINGTON UNIVERSITY · PI William G. Powderly · 2017 to 2026
$97.8MWashington University Institute of Clinical and Translational SciencesUL1TR000448 · NCATS · WASHINGTON UNIVERSITY · PI EVANOFF, BRADLEY A · 2012 to 2016
$41.4MWashington University Nutrition Obesity Research CenterP30DK056341 · NIDDK · WASHINGTON UNIVERSITY · PI Brian N Finck · 1999 to 2026
$30.2MWU P&FP30DK020579 · NIDDK · WASHINGTON UNIVERSITY · PI Jennifer Lynn Powers Carson · 2013 to 2026
$27.1MTRANSGENICS COREP60DK020579 · NIDDK · WASHINGTON UNIVERSITY · PI SCHAFFER, JEAN E. · 1986 to 2012
$25.2MPRINCIPLES IN PULMONARY RESEARCHT32HL007317 · NHLBI · WASHINGTON UNIVERSITY · PI Steven Brody, Michael J Holtzman · 1985 to 2026
$16.1MUniversiity of Rochester Center for Medical Countermeasures against RadiationU19AI091036 · NIAID · UNIVERSITY OF ROCHESTER · PI WILLIAMS, JACQUELINE PATRICIA · 2010 to 2014
$15.6MTrainingP41GM103422 · NIGMS · WASHINGTON UNIVERSITY · PI YARASHESKI, KEVIN E · 2012 to 2019
$12.0MROLE OF INDUCIBLE BRONCHUS ASSOCIATED LYMPHOID TISSUE IN LATENT TUBERCULOSISR01AI111914 · NIAID · WASHINGTON UNIVERSITY · PI KAUSHAL, DEEPAK, KHADER, SHABAANA A. · 2015 to 2025
$11.1MROLE OF IL-17 IN PROTECTIVE VACCINE-INDUCED IMMUNE RESPONSES AGAINST TUBERCULOSISR01HL105427 · NHLBI · WASHINGTON UNIVERSITY · PI KHADER, SHABAANA A. · 2011 to 2025
$5.9MCOMMON IMMUNE CORRELATES OF RISK OF TB DISEASE IN ANIMAL MODELS AND HUMANSR01AI123780 · NIAID · WASHINGTON UNIVERSITY · PI KAUSHAL, DEEPAK, KHADER, SHABAANA A. · 2016 to 2019
$2.9MNCATS NIH HHS UL1 TR000448NCATS NIH HHS UL1 TR002345NCI NIH HHS P30 CA091842NHLBI NIH HHS R01 HL105427NHLBI NIH HHS T32 HL007317NIAID NIH HHS R01 AI111914NIAID NIH HHS R01 AI123780NIAID NIH HHS U19 AI091036NIDDK NIH HHS P30 DK020579NIDDK NIH HHS P30 DK056341NIDDK NIH HHS P60 DK020579NIGMS NIH HHS P41 GM103422
Abstract
Tuberculosis is a significant global health threat, with one-third of the world's population infected with its causative agent Mycobacterium tuberculosis (Mtb). The emergence of multidrug-resistant (MDR) Mtb that is resistant to the frontline anti-tubercular drugs rifampicin and isoniazid forces treatment with toxic second-line drugs. Currently, ~4% of new and ~21% of previously treated tuberculosis cases are either rifampicin-drug-resistant or MDR Mtb infections
Indexed as
Host-Pathogen InteractionsAnimalsAntitubercular AgentsBacterial ProteinsCells, CulturedCell WallDNA-Directed RNA PolymerasesDrug Resistance, Multiple, BacterialFemaleGene ExpressionInterferon-betaInterleukin-1LipidsMacrophagesMaleMiceAntitubercular AgentsBacterial ProteinsDNA-Directed RNA PolymerasesInterferon-betaInterleukin-1Lipidsphthiocerol dimycocerosateReceptors, Interleukin-1RifampinrpoB protein, Mycobacterium tuberculosis
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.